Table 1.

Basic characteristics of the eligible clinical trials.

First author	Phase	Journal	Publication year	Registered number	Groups	No. patents	Dose
Santoro et al. (16)	Open-label randomized phase 3 trial	Journal of Clinical Oncology	1995	NA	A	263	A: 75 mg/m2, every 3 weeks at least 2 cycles
					AI	258	A: 50 mg/m2 + I: 5 g/m2, every 3 weeks at least 2 cycles
Maurel et al. (17)	Open-label randomized phase 2 trial	Journal of Clinical Oncology	2009	NA	A	67	A: 75 mg/m2, every 3 weeks for 6 cycles
					AI	65	A: 90 mg/m2, every 2 weeks for 3 cycles + I: 12.5 g/m2, every 3 weeks for 3 cycles
Judson et al. (18)	Open-label randomized phase 3 trial	Lancet Oncology	2014	NCT00061984	A	228	A: 75 mg/m2, every 3 weeks for 6 cycles
					AI	227	A: 75 mg/m2 + I: 10 g/m2, every 3 weeks for 6 cycles

A, doxorubicin; I, ifosfamide; NA, not available.